About 300,000 patients nationally suffer from degradation of the aortic heart valve, which forces the heart to work harder to pump blood, often leading to heart failure, blood clots and sudden death.
FDA approved the Sapien 3 transcatheter aortic valve replacement (TAVR) platform for treatment of severe aortic stenosis early in the disease process while patients still had no symptoms or other ...
SAN FRANCISCO -- For selected patients with mitral regurgitation (MR), the Sapien M3 device delivered highly promising 1-year outcomes for the desperate field of transcatheter mitral valve replacement ...
LONDON--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced one-year data highlighting the continued outstanding performance of its SAPIEN 3 Ultra RESILIA valve. The data were presented ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results